Highly frequent pathogenic mutation in the CD200R1 gene in population of MS affected women in Khuzestan province

Document Type : Research Paper


1 Department of Genetics, Faculty of Sciences, Shahid Chamran University of Ahvaz, Ahvaz, Iran. Biotechnology and bioscience research center, Shahid Chamran, University of Ahvaz, Ahvaz, Iran.

2 Department of Genetics, Azad Islamic University, Branch Shahr-e-Kord, Shahr-e-Kord.Iran.

3 Khuzestan Multiple Sclerosis Society, Rehabilitation Faculty, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.


Introduction: Multiple sclerosis is an inflammatory neuromuscular disease in which the myelin sheaths of the neural cells are damaged in the brain and spinal cord. Aside from environmental factors, MS disease can be a result of genetic impairment. This study examined the frequency of p.H182fs mutation in the CD200R1 gene, which was observed in a MS affected identical twin by whole exome sequencing.
Methods: For this purpose, 50 unrelated women with MS disease and 50 healthy women with negative history for neurodegenerative disorders in their families and relatives were selected to examine the frequency of the detected change. After extracting the genome and designing the primer, amplification of desired exon was performed by PCR resulting to a bp243 fragment containing the mutation p.H182fs. PCR product was sequenced by Sanger method, subsequently.
Results: The mutation was present in 32% of patients in homozygous or heterozygous mode. No healthy women showed the mentioned mutation.
Conclusion: This implies the achievement of the CD200R1 gene as one of the candidates for MS pathogenesis, at least for a part of patients in province Khuzestan.


  1. 1.     Compston A, Coles A. Multiple sclerosis. Lancet. 2008: 372; 1502-17.2.     Marie Therese Fischer,l, Isabella Wimmer,l, Romana Ho ftberger,2 Susanna Gerlach,l Lukas Haider,l Tobias Zrzavy,l Simon Hametner,l Don Mahad,3 Christoph J. Binder,4 Markus Krumbholz,5 Jan Bauer,l Monika Bradll and Hans Lassmannl. Disease-specific molecular events in cortical multiple sclerosis lesions.  Brain. 2013: 136(6); 1799-815.

    1. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron. 2006: 52(1); 61-76.
    2. El-Etr M, Ghoumari A, Sitruk-Ware R, Schumacher M. Hormonal influences inmultiple sclerosis: new therapeutic benefits for steroids. Maturitas. 2011: 68(1); 47-51.
    3. Zuvich R, McCauley JL, Pericak-Vance MA, Haines JL. Genetics and pathogenesis of multiple sclerosis. Semin Immunol. 2009: 21(6); 328-33.
    4. Draper T. Multiple Sclerosis: A Reappraisal. J Neurol Neurosurg Psychiatry. 1973: 36(5); 893-4.
    5. Bagert B, Camplair P, Bourdette D. Cognitive dysfunction inmultiple sclerosis: natural history,pathophysiology and management. CNS drugs. 2002: 16(7); 445-55.
    6. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurol. 1996: 46(4), 907-11.

    9.       McFarland HF, Martin R. Multiple sclerosis:a complicated picture of autoimmunity. Nat Immunol. 2007: 8(3); 909-13.10.    Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol. 2004: 3(2); 104-10.

    1. Pierrot-Deseilligny C. Clinical implications of a possible role of vitamin D in multiple sclerosis. J neurol. 2009: 256(9); 1468-79.

    12.    Etemadifar M, Sajjadi S, Nasr Z, Firoozeei TS, Abtahi SH, Akbari M,Fereidan-Esfahani M. Epidemiology of multiple sclerosis in Iran: a systematic review. Eur Neurol. 2013: 70(5-6); 356-63.13.    Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. PartI: the role of infection. Ann Neurol. 2007: 661(4); 288-99.14.    Ascherio A. Environmental factors in multiple sclerosis. Expert Rev Neurother. 2013: 3(12); 3-9.15.    Pakpoor J, Ramagoopalan V. Epestein-Barr virus is necessary causative agent in the pathogenesis of multiple sclerosis: yes. Multiple Sclerosis. 2013: 19(13); 1601- 9.

    1. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2005: 23; 683-747.
    2. Etemadifar M, Janghorbani M, Shaygannejad V, Ashtari F. prevalence of multiple sclerosis in isfahan, Iran. Neuroepidemiol. 2006: 27(1); 39-44.

    18.    Branzinie S. E, Revealing the genetic basis of multiple sclerosis: Are we there yet. NIH public access. 2011: 21(3); 317-24.

    1. Nair A, Frederick T.J and Miller S.D. Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci. 2008: 65(17); 2702-20.
    2. Steinman L. Multiple sclerosis: a two-stage disease. Nat immunol. 2001: 2(9); 762-3.
    3. Benveniste EN. Cytokines: influence on glial cell gene expression and function. Chem Immunol. 1997: 69; 31-75.
    4. Aravalli RN, Peterson PK, Lokensgard JR. Toll-like receptors in defense and damage of the central nervous system. JNeuroimmune Pharmacol. 2007: 2(4); 297-312.

    23.    Watson CT, Disanto G, Breden F, Giovannoni G, Ramagopalan SV. Estimating the proportion of variation in susceptibility to multiple sclerosis captured by common SNPs. Sci Rep. 2012: 2;770.

    1. Schmidt H, Williamson D, Ashley-Koch A. HLA-DR15 haplotype and multiple sclerosis: a HuGE review. Am J Epidemiol. 2007: 165(10): 1097-109.
    2. Yeo TW, De Jager PL, Gregory SG, Barcellos LF, Walton A, Goris A, Fenoglio C, Ban M, Taylor CJ, Goodman RS, Walsh E, Wolfish CS, Horton R, Traherne J, Beck S, Trowsdale J, Caillier SJ, Ivinson AJ, Green T, Pobywajlo S, Lander ES, Pericak-Vance MA, Haines JL, Daly MJ, Oksenberg JR, Hauser SL, Compston A, Hafler DA, Rioux JD, Sawcer S. A second major histocompatibility complex susceptibility locus for multiple sclerosis. Ann neurol. 2007: 61(3); 228-36.

    26.    Nathalie Koning, Lars Bo, Robert M, Hoek, Inge Huitinga. Down- regulation of macrophage inhibitory molecules in multiple sclerosis lesions. Ann of Neurol. 2007: 62 (5); 504-14.

    1. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noorts S, Weinshenker BY, Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann neurol. 2005: 50(1); 121-7.
    2. Inglese M. Multiple sclerosis: new insights and trends. AJNR Am J Neuroradiol. 2006: 27(5); 954-7.
    3. Wright GJ, Puklavec MJ, Willis AC, Hoek RM, Sedgwick JD, Brown MH, Barclay AN. Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function. Immunity. 2000: 13(2): 233-42.
    4. Dick AD, Broderick C, Forrester JV, Wright GJ. Distribution of OX2 antigen and OX2 receptor within retina. Invest Ophthalmol Vis Sci. 2001: 42(1); 170–6.
    5. Wright GJ1, Cherwinski H, Foster Cuevas M, Brooke G, Puklavec MJ, Bigler M, Song Y, Jenmalm M, Gorman D, McClanahan T, Liu MR, Brown MH, Sedgwick JD, Phillips JH, Barclay AN. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol. 2003:171(6); 3034-46.
    6. Cherwinski HM, Murphy CA, Joyce BL, Bigler ME, Song YS, Zurawski SM, Moshrefi MM, Gorman DM, Miller KL, Zhang S, Sedgwick JD, Phillips JH. The CD200 receptor is a novel and potent regulator of murine and human mast cell function. J Immunol. 2005: 174(3); 1348-56.